Subsidiary of Alimera Sciences to Distribute ILUVIEN in the Middle East

Alimera Sciences B.V., a subsidiary of pharmaceutical company Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), has signed an agreement with MEAgate International FZLLC (MEAgate) to distribute ILUVIEN® throughout much of the Middle East.
According to the press release:

The countries included in the agreement are Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, UAE, and Yemen, where an estimated 16 million people today are living with diabetes.
MEAgate is led by a seasoned management team with more than 35 years of pharmaceutical and medical device experience in the Middle East including tenure with Merck, Medtronic and GE Healthcare. In addition to the management team’s experience, the board of directors is comprised of individuals with extensive pharmaceutical distribution experience throughout the Middle East.
Under the terms of the agreement, MEAgate will open a scientific office for Alimera in the Middle East to support regulatory, medical affairs, and sales and marketing operations. In addition to its administrative and regulatory support personnel, MEAgate will initially have a team of five Medical Science Liaisons, with two in Saudi Arabia, two in Egypt and one in the Gulf Cooperation Council countries, to support Named Patient Sales, which are expected to begin in Saudi Arabia, Egypt, UAE and Lebanon in 2016. Named Patient Sales is an early access program where health authorities allow selected institutions to provide globally approved innovative medications to their patients while the products are still in the process of approval and full registration. MEAgate will assist Alimera in registering ILUVIEN in all countries included in the agreement.

 
Click here to read the full press release.